Navigation Links
Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System

CLEVELAND, Aug. 3 /PRNewswire/ -- Researchers at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, a national leader in the early adoption and use of advanced treatments for cancer patients, will soon become the first in the world to test an innovative radiotherapy system from ViewRay™, Inc. The ViewRay system is designed to improve the accuracy of cancer treatments through a combination of medical imaging and radiotherapy delivery.*

Radiation therapy is critical in the fight against cancer, and nearly two-thirds of all cancer patients receive radiation therapy during their illness. However, patients and their internal organs naturally and continually move during treatment, preventing clinicians from determining precisely where the radiation is going in a patient's body. The ViewRay system is being designed to provide continuous soft-tissue MRI during treatment so that clinicians can see precisely where the radiation is being delivered, potentially improving treatment success and reducing side effects.

"This is a tremendous opportunity for us to lead the region in the implementation of real-time MRI guidance for radiation therapy for cancer patients," said Dennis Hallahan, MD, FASTRO, head of radiation oncology at the Siteman Cancer Center. "The problem of patient organ motion is one that needs to be solved. We believe the ViewRay technology holds great potential for treating patients with cancers in parts of the body that are sensitive to motion, such as the head and neck, lung, prostate and cervix. The technology fits perfectly with our mission to advance the field of cancer therapy."

"We couldn't have asked for a better partner for our technology," said ViewRay president and CEO Gregory M. Ayers, MD, PhD. "Washington University researchers are known for their groundbreaking scientific investigation and for their translation of new discoveries into meaningful clinical treatments. We are excited to be working with them to test and refine a system we believe will offer a significant advancement in radiation therapy."

* At this time, the ViewRay system is for nonclinical research use only.

About ViewRay

ViewRay, Inc., of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. Using MRI-guided radiotherapy, the ViewRay system is intended to provide continuous soft-tissue imaging during treatment. The system is being designed so that clinicians—for the first time—will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy, potentially improving outcomes and reducing side effects. For more information, visit

About the Siteman Cancer Center

The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is the only National Cancer Institute Comprehensive Cancer Center in Missouri and within a 240-mile radius of St. Louis. Siteman is also one of only 20 national members of the National Comprehensive Cancer Network, an alliance of the world's leading cancer centers dedicated to improving the quality, effectiveness and efficiency of oncology practice so patients can live better lives. For more information, visit .

ViewRay is a trademark of ViewRay, Inc.

SOURCE ViewRay Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 Une ... photodynamique au Bremachlorin contre le cancer avancé. ... à combiner l,immunothérapie au traitement photodynamique au Bremachlorin ... Une nouvelle approche consistant à combiner ... cancer avancé.    Clinical Cancer ...
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, Inc. ... has completed the acquisition of Kremers Urban Pharmaceuticals ... of global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... Lannett has acquired KU from UCB for total ... adjustments, including a customary working capital adjustment, a ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
Breaking Medicine Technology:
(Date:11/29/2015)... , ... November 29, 2015 , ... Effective immediately, every ... In addition starting on Black Friday Target is offering a “Buy One Scrub Set, ... is a rare opportunity to purchase IguanaMed at a discounted price. , ...
(Date:11/28/2015)... ... ... Safe storage for contraceptive devices may not always be easy to find. However, ... other from Bradley Beach, New Jersey, there is an easy solution to the problem. ... NuvaRings more often than necessary. As such, it affords peace of mind and eliminates ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is ... panels to choose from, the possibilities are endless. Users have full control over angle ... ProPanel: Pulse masking effects, users are sure to get heads to turn. , ProPanel: ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Toronto and the University of British Columbia suggested that laws requiring bicyclists to wear ... explains that part of the reason for the controversial conclusion is that, while helmets ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released a ... Mesothelioma has just posted the findings on the website. Click here to read ... of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among ...
Breaking Medicine News(10 mins):